Legend Biotech Corp
LEGN34.320USD
+0.040+0.12%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
6.30BCap. mercado
PérdidaP/E TTM
Más Datos de Legend Biotech Corp Compañía
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Información de la empresa
Código de la empresaLEGN
Nombre de la empresaLegend Biotech Corp
Fecha de salida a bolsaJun 04, 2020
Fundada en2015
Director ejecutivoDr. Ying Huang, Ph.D.
Número de empleados2600
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 04
Dirección2101 Cottontail Lane
CiudadSOMERSET
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal08873
Teléfono17328505598
Sitio Webhttps://investors.legendbiotech.com/
Código de la empresaLEGN
Fecha de salida a bolsaJun 04, 2020
Fundada en2015
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
579.05M
92.32%
Europe
47.87M
7.63%
China
320.00K
0.05%
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: sáb., 26 de abr
Hora de actualización: sáb., 26 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Fidelity Management & Research Company LLC
6.38%
RA Capital Management, LP
4.09%
T. Rowe Price Associates, Inc.
3.70%
HHLR Advisors, Ltd.
3.26%
Westfield Capital Management Company, L.P.
3.11%
Other
79.46%
Estadísticas de accionistas
Accionista
Proporción
Fidelity Management & Research Company LLC
6.38%
RA Capital Management, LP
4.09%
T. Rowe Price Associates, Inc.
3.70%
HHLR Advisors, Ltd.
3.26%
Westfield Capital Management Company, L.P.
3.11%
Other
79.46%
Tipo
Accionista
Proporción
Investment Advisor
19.55%
Investment Advisor/Hedge Fund
18.45%
Hedge Fund
13.79%
Research Firm
2.70%
Corporation
1.25%
Venture Capital
0.53%
Bank and Trust
0.30%
Sovereign Wealth Fund
0.09%
Individual Investor
0.08%
Other
43.26%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
539
104.38M
56.84%
-4.11M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
2023Q3
468
90.50M
49.93%
-2.81M
2023Q2
459
88.99M
49.23%
+9.84M
2023Q1
421
72.14M
43.70%
-3.07M
2022Q4
415
67.29M
40.76%
-7.51M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
11.71M
6.38%
-4.86M
-29.35%
Dec 31, 2024
RA Capital Management, LP
7.51M
4.09%
--
--
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.80M
3.7%
-4.36M
-39.04%
Dec 31, 2024
HHLR Advisors, Ltd.
5.98M
3.26%
-651.95K
-9.82%
Dec 31, 2024
Westfield Capital Management Company, L.P.
5.71M
3.11%
+675.19K
+13.40%
Dec 31, 2024
Suvretta Capital Management, LLC
3.50M
1.9%
+3.50M
--
Dec 31, 2024
Invesco Advisers, Inc.
3.29M
1.79%
+1.02M
+45.16%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.26M
1.77%
-21.07K
-0.64%
Dec 31, 2024
Braidwell LP
2.98M
1.62%
+1.44M
+93.18%
Dec 31, 2024
Citadel Advisors LLC
2.90M
1.58%
+1.59M
+120.64%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Harbor Health Care ETF
7.94%
Matthews Emerging Markets Sustainable Future Active ETF
4.28%
Matthews Emerging Markets Discovery Active ETF
3.82%
Global X Genomics & Biotechnology ETF
3.72%
Tema Oncology ETF
2.77%
KraneShares MSCI All China Health Care Index ETF
1.77%
Virtus LifeSci Biotech Products ETF
1.59%
Range Cancer Immunotherapy ETF
1.2%
iShares Biotechnology ETF
0.4%
WisdomTree China ex-State-Owned Enterprises Fund
0.31%
Ver más
Harbor Health Care ETF
Proporción7.94%
Matthews Emerging Markets Sustainable Future Active ETF
Proporción4.28%
Matthews Emerging Markets Discovery Active ETF
Proporción3.82%
Global X Genomics & Biotechnology ETF
Proporción3.72%
Tema Oncology ETF
Proporción2.77%
KraneShares MSCI All China Health Care Index ETF
Proporción1.77%
Virtus LifeSci Biotech Products ETF
Proporción1.59%
Range Cancer Immunotherapy ETF
Proporción1.2%
iShares Biotechnology ETF
Proporción0.4%
WisdomTree China ex-State-Owned Enterprises Fund
Proporción0.31%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos